| Description |
Recombinant Mouse LOX1 Protein is expressed from HEK293 with His tag at the N-Terminus.It contains Arg60-Ile363. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q9EQ09 |
| Target Symbol |
LOX1 |
| Synonyms |
Ox-LDL receptor 1; LOX-1; CLEC8A; LOX1; OLR1; LOXIN; SR-E1; SCARE1; SLOX1 |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
N-His |
| Expression Range |
Arg60-Ile363 |
| Mol. Weight |
The protein has a predicted MW of 36.1 kDa. Due to glycosylation, the protein migrates to 55-63 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
LOX-1 is a transmembrane glycoprotein that binds to and internalizes ox-LDL.LOX-1 gene deletion in mice and anti-LOX-1 therapy has been shown to decrease inflammation, oxidative stress and atherosclerosis. LOX-1 deletion also results in damage from ischemia, making LOX-1 a promising target of therapy for atherosclerosis and related disorders. In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis. |
